Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-T1D-2: Tirzepatide in adults with type 1 diabetes and overweight/obesity
2024-519685-51-00Phase 3Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D), obesity and Overweight comparing Tirzepatide once weekly with Placebo once weekly (2 arms). Primary endpoint: Change from baseline in hemoglobin A1c (HbA1c) at Week 40. Planned start Jun 2025; status: authorised.
02
Drugs
03
Conditions
diabetes mellitus type 1 (T1D)obesityOverweight
Beyond the preview
Go deeper on 2024-519685-51-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519685-51-00.